Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): A second line treatment option

被引：20

作者：

Razak, Albiruni Ryan Abdul ^{[1
]}

Chatten, Katy J. ^{[1
]}

Hughes, Andrew N. ^{[1
]}

机构：

[1] Newcastle Gen Hosp, No Ctr Canc Treatment, Dept Med Oncol, Newcastle Upon Tyne NE4 9XF, Tyne & Wear, England

来源：

LUNG CANCER | 2008年 / 60卷 / 02期

关键词：

mesothelioma; pemetrexed; second line; retreatment; chemotherapy; response;

D O I：

10.1016/j.lungcan.2007.08.031

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The role of second line treatment in malignant pleural mesothelioma (MPM) is currently undefined. We present four cases of patients who had durable responses from pernetrexed-based chemotherapy who were retreated with a similar regimen upon progression of their mesothelioma. This case series explores the possible role of retreatment with pernetrexed-based chemotherapy as a second line therapeutic option in MPM. (C) 2007 Elsevier Ireland Ltd. All rights reserved.

引用

页码：294 / 297

页数：4

共 5 条

[1] Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma [J].